News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
413,826 Results
Type
Article (18061)
Company Profile (122)
Press Release (395636)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (136024)
Career Advice (869)
Deals (24694)
Drug Delivery (71)
Drug Development (47823)
Employer Resources (70)
FDA (8734)
Job Trends (8657)
News (221319)
Policy (18791)
Tag
Academia (696)
Accelerated approval (6)
Adcomms (9)
Allergies (58)
Alliances (31534)
ALS (63)
Alzheimer's disease (644)
Antibody-drug conjugate (ADC) (72)
Approvals (8824)
Artificial intelligence (179)
Autoimmune disease (22)
Automation (8)
Bankruptcy (212)
Best Places to Work (6157)
BIOSECURE Act (10)
Biosimilars (92)
Biotechnology (57)
Bladder cancer (44)
Brain cancer (25)
Breast cancer (153)
Cancer (1397)
Cardiovascular disease (148)
Career advice (749)
Career pathing (14)
CAR-T (74)
CDC (6)
Cell therapy (218)
Cervical cancer (8)
Clinical research (40630)
Collaboration (652)
Compensation (444)
Complete response letters (26)
COVID-19 (995)
CRISPR (45)
C-suite (354)
Cystic fibrosis (63)
Data (1667)
Denatured (16)
Depression (35)
Diabetes (152)
Diagnostics (2965)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (20)
Drug discovery (85)
Drug pricing (103)
Drug shortages (13)
Duchenne muscular dystrophy (82)
Earnings (59589)
Editorial (21)
Employer branding (13)
Employer resources (66)
Events (64498)
Executive appointments (683)
FDA (9809)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (507)
Gene editing (70)
Generative AI (11)
Gene therapy (200)
GLP-1 (478)
Government (1702)
Grass and pollen (4)
Guidances (230)
Healthcare (7490)
HIV (15)
Huntington's disease (11)
IgA nephropathy (27)
Immunology and inflammation (86)
Immuno-oncology (4)
Indications (29)
Infectious disease (1052)
Inflammatory bowel disease (82)
Inflation Reduction Act (7)
Influenza (21)
Intellectual property (86)
Interviews (109)
IPO (11101)
IRA (37)
Job creations (2748)
Job search strategy (681)
Kidney cancer (10)
Labor market (26)
Layoffs (287)
Leadership (11)
Legal (5085)
Liver cancer (37)
Longevity (7)
Lung cancer (197)
Lymphoma (115)
Machine learning (7)
Management (22)
Manufacturing (318)
MASH (70)
Medical device (4747)
Medtech (4753)
Mergers & acquisitions (14096)
Metabolic disorders (459)
Multiple sclerosis (43)
NASH (17)
Neurodegenerative disease (65)
Neuropsychiatric disorders (15)
Neuroscience (1030)
NextGen: Class of 2025 (2868)
Non-profit (1193)
Now hiring (16)
Obesity (235)
Opinion (165)
Ovarian cancer (40)
Pain (95)
Pancreatic cancer (47)
Parkinson's disease (78)
Partnered (11)
Patents (189)
Patient recruitment (106)
Peanut (18)
People (41503)
Pharmaceutical (65)
Pharmacy benefit managers (14)
Phase I (11271)
Phase II (17437)
Phase III (14820)
Pipeline (1630)
Policy (129)
Postmarket research (1729)
Preclinical (4542)
Press Release (72)
Prostate cancer (89)
Psychedelics (15)
Radiopharmaceuticals (185)
Rare diseases (308)
Real estate (3800)
Recruiting (26)
Regulatory (13528)
Reports (24)
Research institute (790)
Resumes & cover letters (126)
Rett syndrome (11)
RNA editing (6)
RSV (11)
Schizophrenia (71)
Series A (86)
Series B (58)
Service/supplier (3)
Sickle cell disease (43)
Special edition (10)
Spinal muscular atrophy (116)
Sponsored (13)
Startups (2230)
State (2)
Stomach cancer (5)
Supply chain (46)
Tariffs (62)
The Weekly (47)
Vaccines (252)
Venture capital (30)
Weight loss (138)
Women's health (14)
Worklife (4)
Date
Today (42)
Last 7 days (215)
Last 30 days (1139)
Last 365 days (16909)
2025 (11889)
2024 (19566)
2023 (22809)
2022 (31096)
2021 (32578)
2020 (30638)
2019 (23683)
2018 (18364)
2017 (19761)
2016 (18575)
2015 (22496)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17457)
2010 (16480)
Location
Africa (443)
Alabama (30)
Alaska (3)
Arizona (104)
Arkansas (4)
Asia (26869)
Australia (3568)
California (4321)
Canada (1645)
China (464)
Colorado (192)
Connecticut (198)
Delaware (121)
Europe (54726)
Florida (753)
Georgia (90)
Hawaii (1)
Idaho (28)
Illinois (355)
India (27)
Indiana (223)
Iowa (8)
Japan (192)
Kansas (79)
Kentucky (24)
Louisiana (8)
Maine (47)
Maryland (504)
Massachusetts (3512)
Michigan (118)
Minnesota (245)
Mississippi (2)
Missouri (46)
Montana (17)
Nebraska (13)
Nevada (45)
New Hampshire (23)
New Jersey (1525)
New Mexico (11)
New York (1146)
North Carolina (726)
North Dakota (5)
Northern California (1970)
Ohio (132)
Oklahoma (7)
Oregon (19)
Pennsylvania (880)
Puerto Rico (11)
Rhode Island (22)
South America (672)
South Carolina (16)
Southern California (1716)
Tennessee (83)
Texas (620)
United States (16448)
Utah (107)
Virginia (167)
Washington D.C. (44)
Washington State (325)
West Virginia (3)
Wisconsin (43)
413,826 Results for "novartis pharmaceuticals corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier
Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.
August 27, 2025
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.
September 3, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
·
2 min read
·
Tristan Manalac
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year.
September 9, 2025
·
2 min read
·
Annalee Armstrong
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.
September 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
September 2, 2025
·
6 min read
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
The partnership with Matchpoint Therapeutics gets Novartis global rights on all molecules for several unannounced inflammatory diseases identified through the biotech’s discovery platform.
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.
July 3, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production.
July 17, 2025
·
2 min read
·
Tristan Manalac
1 of 41,383
Next
